Study identification

EU PAS number

EUPAS40313

Study ID

44600

Official title and acronym

Trelegy Ellipta general drug use investigation (asthma)

DARWIN EU® study

No

Study countries

Japan

Study description

Post-marketing surveillance to collect and assess information regarding the safety and effectiveness of Trelegy Ellipta in asthma patients under the actual use conditions.

Study status

Finalised
Research institutions and networks

Institutions

Contact details

GSK Clinical Disclosure Advisor GSK Clinical Disclosure Advisor Pharma.CDR@gsk.com

Study contact

GSK Clinical Disclosure Advisor GSK Clinical Disclosure Advisor

Primary lead investigator
Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

GlaxoSmithKline
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Non-EU RMP only